Company intelligence / Profile preview
Isocell
Paris, Franceisocell.fr ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Laboratoires Isocell is a French life sciences company specializing in the study of oxidative stress and the development of antioxidant-based therapies and supplements. Founded in 1995, the company is best known for its proprietary GliSODin technology, which represents the first orally effective form of Superoxide Dismutase (SOD) combined with a wheat protein (gliadin) to ensure bioavailability. Isocell focuses on dermatological and systemic health applications, including the treatment of vitiligo, skin aging, and UV-induced damage. The company operates globally, providing both finished products and patented ingredients for the pharmaceutical, cosmetic, and nutraceutical industries.
- Therapeutic areas
- CardiovascularDermatologyMetabolic Disorders
- Modalities
- ProteinSmall moleculeNutraceutical
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Isocell.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Isocell.